Inogen (INGN) Cash & Equivalents (2012 - 2026)

Inogen (INGN) has 15 years of Cash & Equivalents data on file, last reported at $93.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 21.68% year-over-year to $93.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.1 million (down 21.68% YoY) and the FY2025 annual result came in at $103.7 million, down 11.66% from the prior year.
• Cash & Equivalents slipped to $93.1 million in Q1 2026 per INGN's latest filing, from $103.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $223.6 million in Q2 2022 and bottomed at $23.7 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $107.4 million (2024), against an average of $125.2 million.
• The widest annual swing landed in 2023, when Cash & Equivalents sank 88.82%; it then jumped 350.23% in 2024.
• Tracing INGN's Cash & Equivalents over 5 years: stood at $187.0 million in 2022, then sank by 32.9% to $125.5 million in 2023, then decreased by 6.44% to $117.4 million in 2024, then dropped by 11.66% to $103.7 million in 2025, then declined by 10.24% to $93.1 million in 2026.
• Per Business Quant, the three latest INGN Cash & Equivalents figures stand at $93.1 million (Q1 2026), $103.7 million (Q4 2025), and $106.5 million (Q3 2025).

Peer Comparison